- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
Salomon Smith Barney and Lehman Brothers bash Altera and Xilinx, sending the whole sector screaming lower.
The software giant falters on sales and valuation concerns, but presents a rosy outlook.